The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday.

Bioluminescent luciferase enzymes have historically been too dim to use as probes in living tissue. But recent advances have ...

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 ...

Shares of CureVac (NASDAQ: CVAC) climbed 11% following a favorable patent validity decision in its legal proceedings against BioNTech (NASDAQ: NASDAQ: BNTX). The ...

The shocking rise of aggressive cancers post-COVID-19 is prompting concerns from health experts about the long-term consequences of mRNA vaccines. One of the world's leading oncologists, Dr. Patrick ...

We recently published a list of Did Jim Cramer Nail or Miss These 14 Stocks? In this article, we are going to take a look at ...

Cronin has worked at Moderna since 2021, when she was brought on to market the biotech company’s COVID-19 vaccine.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $70.0 for Moderna over the recent three months. In terms of liquidity ...

We recently published a list of 10 Stocks To Trade Without Tariffs And Interest Rate Fears. In this article, we are going to ...

Average-Risk Patient Study Seeks to Confirm Mainz Biomed's Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples Study is on Track to Report ...

Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed” or the "Company”), a molecular genetics diagnostic company specializing in ...

German research institutions could benefit, but they’ re also concerned about Trump’ s impact on global science.Mass layoffs, frozen or cut research funds, political directives-- US President Donald ...